Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Bristol-Myers Squibb

X
Drug Profile

Research programme: cancer therapeutics - Bristol-Myers Squibb

Alternative Names: BMS-536924; BMS-554417; BMS-673675; BMS-695735; BMS-698769; BMS-738533; BMS-743816; BMS-794833; BMT 062789

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Aminopyridines; Benzimidazoles; Heterocyclic compounds; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Epidermal growth factor receptor antagonists; IGF type 1 receptor antagonists; Mitogen-activated protein kinase inhibitors; Proto-oncogene protein c-met inhibitors; Receptor protein-tyrosine kinase antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 03 Dec 2016 Interim pharmacodynamics data from a preclinical studies in Lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Nov 2010 Preclinical trials in Cancer in China (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top